stockrow
Monday 9 November 2026
Export ALMR’s income statement to Excel — free account
Alamar Biosciences, Inc.
ALMRAlamar Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.2 million, up 195.2% from fiscal 2024.
- Revenue
- +68.5%
- EPS
- +72.0%
- Free cash flow
- +1.07%
Quarter to September 2026, against a year earlier
28.05
1.14
+4.24%
Follow ALMR
Alert me
Alamar Biosciences, Inc. (ALMR) P/E ratio
Alamar Biosciences, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 0.0× | — |
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| 3 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ALMR Alamar Biosciences, Inc. | n/m |
| BFLY Butterfly Network, Inc. compare | n/m |
| ESTA Establishment Labs Holdings Inc. compare | n/m |
| NVCR NovoCure Limited compare | n/m |
| ENOV Enovis Corporation compare | n/m |
| INSP Inspire Medical Systems, Inc. compare | 18.4× |
| TMDX TransMedics Group, Inc. compare | 21.0× |
| CNMD CONMED Corporation compare | 21.3× |
| UFPT UFP Technologies, Inc. compare | 30.6× |
| Medical Devices industry median | 24.9× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)